Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.52 |
| ▸ | APP | P05067 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17971252 | 0.93 | ENPP2 (0.62) | ENPP2APPMAPTSMN1; SMN2LMNA | |
| SCHEMBL17971229 | 0.88 | APP (0.57) | ENPP2APPMAPTSMN1; SMN2LMNA | |
| SCHEMBL17971224 | 0.87 | APP (0.54) | ENPP2APPMAPTSMN1; SMN2LMNA | |
| SCHEMBL17958300 | 0.87 | ENPP2 (0.69) | ENPP2APPMAPTTHRBPTGDR2 | |
| SCHEMBL16596281 | 0.87 | ENPP2 (0.69) | ENPP2APPMAPTTHRBPTGDR2 | |
| SCHEMBL16596376 | 0.86 | ENPP2 (0.56) | ENPP2APPMAPTSMN1; SMN2LMNA | |
| SCHEMBL19156065 | 0.85 | APP (0.53) | ENPP2APPMAPTSMN1; SMN2LMNA | |
| SCHEMBL17971221 | 0.85 | ENPP2 (0.55) | ENPP2APPMAPTSMN1; SMN2LMNA | |
| SCHEMBL17971216 | 0.85 | APP (0.66) | ENPP2APPMAPTSMN1; SMN2LMNA | |
| SCHEMBL26552282 | 0.84 | PTGDR2 (0.49) | ENPP2APPMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714240-B2 | Vinyl autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160222000-A1 | VINYL AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222000-A1 | VINYL AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINB10 | ENPP2 1/4885APP 1099/4885MAPT 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.